Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
75 hedge funds and large institutions have $265M invested in Accelerate Diagnostics in 2014 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 8 reducing their positions, and 5 closing their positions.
388% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 8
380% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 5
37% more capital invested
Capital invested by funds: $194M → $265M (+$71.9M)
34% more funds holding
Funds holding: 56 → 75 (+19)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
44% less call options, than puts
Call options by funds: $3.68M | Put options by funds: $6.53M
Top Buyers
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
-$12.7M |
| 2 |
Goldman Sachs
New York
|
-$2.51M |
| 3 |
HCS
Harvest Capital Strategies
San Francisco,
California
|
-$1.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$377K |
| 5 |
BWP
BSW Wealth Partners
Boulder,
Colorado
|
-$240K |
AXDX Hedge Fund Activity: Q2 2014 in Review
75 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2014, worth a combined $265M — up 37% from $194M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AXDX positions and 5 closed out — a net gain of 19 holders — while 39 added to existing stakes and 8 trimmed.
The largest buyer was Oracle Investment Management, adding an estimated $13.4M. The largest seller was Invesco, exiting entirely with an estimated $12.7M sold.
- 75 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2014, up from 56 in Q1 2014.
- Funds reported $265M of Accelerate Diagnostics stock for Q2 2014, up 37% quarter-over-quarter.
- 24 funds opened new Accelerate Diagnostics positions in Q2 2014 and 5 closed out, a net change of +19 holders.
- The largest Accelerate Diagnostics buyer in Q2 2014 was Oracle Investment Management, an estimated $13.4M added.
- The largest Accelerate Diagnostics seller in Q2 2014 was Invesco, an estimated $12.7M sold.
Based on aggregated 13F filings for Q2 2014.